BCTX

BriaCell Therapeutics Corporationdistress 7/10 · high distress / dilution risk

$3.60-4%today-83% from 52w high

briacell.comWest Vancouver, BCBiotechnology

Oncology 2

Lead: Breast Cancer · target PD-1 · est. market ~$35B (approx, global)

Revenue

pre-revenue

Liquidity

$23M

Runway

0.8 yrs

Shares 1y

+362%

Price & events

-18.4% over 6M

CatalystRating changeDilutionFinancingdashed = today

-4.0%

-8.6%

+19.6%

-7.9%

-18.4%

-55.6%

-47.8%

-91.8%

-91.4%

All

Overview

Market Cap: $31.32M
Volume: 60.70K
52 Week Range: $2.74 – $20.70
Total Shares: 8.70M
Float Shares: 7.86M
Short %: 4.37%
% Held by Insiders: 0.51%
% Held by Institutions: 5.25%
RVOL: 0.35x
Beta: 1.54

Pipeline stages · 3 programs

SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-12

SV-BR-1-GM, Low dose cyclophosphamide, Interferon Inoculation

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

BC1 cell line, Bria-OTS regimen and CPI (tislelizumab), Bria-OTS regimen and CPI (tislelizPD-1

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

Pipeline · 3 trials · 1 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2027-12 Estimated 50% readout ~2028-02-14	Phase 3	SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site	Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer	—	recruiting
2026-03-24	Phase 1/2	SV-BR-1-GM, Low dose cyclophosphamide, Interferon Inoculation	Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic	36	completed
2025-04-30	Phase 1/2	BC1 cell line, Bria-OTS regimen and CPI (tislelizumab), Bria-OTS regimen and CPI (tisleliz	Breast Cancer, Breast Tumor, Cancer of Breast, Cancer of the Breast, Malignant Tumor of Breast, Tumors, Breast	18	recruiting